0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
Cardiac Protection in HER2-Targeted Treatment How Should We Measure New Strategies?
Ana Barac, MD, PhD; Sandra M. Swain, MD
JAMA Oncology
Original Investigation  | 
Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial
Annelies H. Boekhout, PhD; Jourik A. Gietema, MD, PhD; Bojana Milojkovic Kerklaan, PhD; et al.
JAMA Oncology
Review  | 
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton, MD, PhD; Sylvia Adams, MD; Mary L. Disis, MD
JAMA Oncology
Original Investigation  | 
Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women A Nationwide Cohort Study
Hsu-Chih Chien, MS; Yea-Huei Kao Yang, BSPharm; Jane P. F. Bai, AM, PhD